血清miR-150-5p和miR-155-5p对老年糖尿病肾病的诊断价值被引量：4

Value of serum miR-150-5p and miR-155-5p in the diagnosis of senile diabetic nephropathy

导出

摘要目的探讨血清miR-150-5p和miR-155-5p在老年糖尿病肾病(DN)中的表达水平及其诊断价值。方法采用实时定量PCR(RT-PCR)法检测2015年1月—2017年12月海南西部中心医院收治的126例老年DN患者(DN组)、140例2型糖尿病患者(2型糖尿病组)和65例健康体检者(对照组)的血清miR-150-5p和miR-155-5p水平。应用受试者工作特征(ROC)曲线分析血清miR-150-5p和miR-155-5p水平对老年DN患者的诊断价值。结果 DN组血清miR-150-5p(3.35±1.26)和miR-155-5p(5.47±1.80)表达水平均高于2型糖尿病组和对照组,差异有统计学意义(P<0.01)。2型糖尿病组与对照组血清miR-150-5p和miR-155-5p表达水平比较,差异无统计学意义(P>0.05)。ROC曲线分析显示,血清miR-150-5p和miR-155-5p诊断老年DN的最佳截值分别为2.65、4.16,灵敏度分别为82.7%和80.3%,特异度为74.8%和83.6%。二者联合诊断老年DN的AUC(95%CI)为0.892(0.834～0.953)优于单项miR-150-5p[0.805(0.749～0.865)]和miR-155-5p[0.837(0.779～0.894)](P<0.05),其灵敏度(90.4%)和特异度(85.7%)最好。结论血清miR-150-5p和miR-155-5p水平在老年DN患者中升高,有望作为老年DN诊断的生物学标志物。 Objective To investigate expression level and diagnostic value of serum miR-150-5p and miR-155-5p inelderly diabetic nephropathy(DN). Methods Serum miR-150-5p and miR-155-5p levels of 126 elderly DN patients(groupDN), 140 patients with type 2 diabetes mellitus(type 2 diabetes group) and 65 healthy persons(control group) were detected byreal-time quantitative PCR(RT-PCR) from January 2015 to December 2017. Diagnostic value of serum miR-150-5p andmiR-155-5p levels in elderly DN patients was analyzed by receiver operating characteristic(ROC) curve. Results Theexpression levels of serum miR-150-5p(3.35±1.26)and miR-155-5p(5.47±1.80)in group DN were significantly higher thanthose in type 2 diabetes group and control group(P<0.01). There was no significant difference in serum miR-150-5p and miR-155-5p levels between type 2 diabetes group and control group(P>0.05). The ROC curve analysis showed that the best cut-offvalues of serum miR-150-5p and miR-155-5p diagnosis of elderly DN were 2.65 and 4.16, respectively. The sensitivity were82.7% and 80.3%, and specificity were 74.8% and 83.6%, respectively. The two combined diagnosis of elderly DN of AUC(95%CI) [0.892(0.834-0.953)] were significantly better than miR-150-5p [0.805(0.749-0.865)] and miR-155-5p [0.837(0.779-0.894)](P<0.05), and its sensitivity(90.4%) and specificity(85.7%) were best. Conclusion Serum miR-150-5p andmiR-155-5p levels in elderly DN patients increase significantly, and it is expected to be a biomarker for the diagnosis of DN inelderly patients.

作者钟开义黎宝仁张祖文蓝燕苏佩琼陈雪丽 ZHONG Kaiyi;LI Baoren;ZHANG Zuwen;LAN Yan;SU Peiqiong;CHEN Xueli(Department of Nephrology ,Central Hospital of Western Hainan ,Danzhou ,Hainan 571799,China)

机构地区海南西部中心医院肾内科

出处《中国热带医学》 CAS 2019年第2期174-176,200,共4页 China Tropical Medicine

基金海南省医学科研基金(No.16A500082)

关键词糖尿病肾病老年人 miR-150-5p miR-155-5p 诊断价值 diabetic nephropathy elderly miR-150-5p miR-155-5p diagnostic value

分类号 R587.1 [医药卫生—内分泌]

作者简介通信作者:钟开义(1978-),男,本科,主治医师,研究方向:临床肾内科疾病。 E-mail:13876251175@163.com.

引文网络
相关文献

参考文献4

1徐爽,梁琳琅,李萍,孔媛.T2DM患者糖尿病肾病的危险因素分析[J].热带医学杂志,2017,17(3):370-372. 被引量：9
2You-qun HUANG Rong GOU Yong-shu DIAO Qing-hua YIN Wen-xing FAN Ya-ping LIANG Yi CHEN Min WU Li ZANG Ling LI Jing ZANG Lu CHENG Ping FU Fang LIU.Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy[J].Journal of Zhejiang University-Science B(Biomedicine & Biotechnology),2014,15(1):58-66. 被引量：23
3王勾琴,王俭勤,梁耀军,何升林,赵鹏鸣,王金华.微小RNA在糖尿病肾病患者血清中的表达及临床意义[J].中华肾脏病杂志,2015,31(7):503-508. 被引量：20
4中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）[J].中国糖尿病杂志,2014,22(8). 被引量：6834

二级参考文献31

1Charlson, M.E., Pompei, P., Ales, K.L., et al., 1987. A new method of classifying prognostic comorbidity in longitu- dinal studies: development and validation. J. Chronic Dis., 40(5):373-383. Idol: 10.1016/0021-9681 (87)90171-8].
2Debella, Y.T., Giduma, H.D., Light, R.P., et al., 2011. Chronic kidney disease as a coronary disease equivalent--a comparison with diabetes over a decade. Clin. J. Am. Soc. Nephrol., 6(6): 1385-1392. [doi: 10.2215/CJN. 10271110].
3de Groot, V., Beckerman, H., Lankhorst, G.J., et al., 2003. How to measure comorbidity: a critical review of availa- ble methods. J. Clin. Epidemiol., 56(3):221-229. [doi: 10. 1016/S0895-4356(02)00585-1].
4Feinstein, A.R., 1970. The pre-therapeutic classification of comorbidity in chronic disease. J. Chronic Dis., 23(7): 455-468. [doi: 10.1016/0021-9681 (70)90054-8].
5Foley, R.N., Parfrey, P.S., Harnett, J.D., et aL, 1996. Hy- poalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J. Am. Soc. Nephrol., 7(5): 728-736.
6Gerstein, H.C., Pogue, J., Mann, J.F., et al., 2005. The rela- tionship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia, 48(9):1749-1755. [doi:10.1007/s00125- OO5-1858-4].
7Guralnik, J.M., 1996. Assessing the impact of comorbidity in the older population. Ann. EpidemioL, 6(5):376-380. [doi: 10. I016/S 1047-2797(96)00060-9].
8Hall, S.F., 2006. A user's guide to selecting a comorbidity index for clinical research. J. Clin. Epidemiol., 59(8): 849-855. [doi:10.1016/j.jclinepi.2005.11.013].
9Keane, W.F., Brenner, B.M., de Zeeuw, D., et al., 2003. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int., 63(4):1499-1507. [doi:10.1046/j.1523-1755. 2003.00885.x].
10Kieszak, S.M., Flanders, W.D., Kosinski, A.S., et al., 1999. A comparison of the Charlson comorbidity index derivedfrom medical record data and administrative billing data. J. Clin. Epidemiol., 52(2):137-142. [doi:10.1016/S0895- 4356(98)00154-1].